市場調查報告書
商品編碼
1043069

幹細胞治療的全球市場:各細胞來源,各類型,各應用領域,各終端用戶,各地區的資訊-至2027年的預測

Stem Cell Therapy Market: Information by Cell Source, by Type, by Application, by End User, and by Region -Forecast till 2027

出版日期: | 出版商: Market Research Future | 英文 132 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球幹細胞治療的市場規模,2020年達57億3,512萬美金,從2020年到2027年的預測期間內預計將有10.74%的年複合成長率。

市場成長,起因於慢性疾病增加,醫療保健產業的擴大,醫療研究的支出增加。再加上幹細胞治療相關臨床研究的數增加,也促進市場成長。可是,初期階段使用幹細胞的治療存在倫理問題,以及大數量的費用,未來有阻礙市場發展的可能性。

本報告提供全球幹細胞治療市場相關調查分析,市場動態,市場分析,競爭情形,企業簡介等系統性資訊。

目錄

第1章 報告開端

第2章 市場簡介

  • 定義
  • 調查範圍
    • 調查目的
    • 假設
    • 限制

第3章 調查手法

  • 簡介
  • 1次調查
  • 2次調查
  • 市場規模的估計

第4章 市場動態

  • 促進因素
  • 阻礙因素
  • 市場機會
  • 課題
  • 宏觀經濟指標
  • 技術趨勢與評估

第5章 市場要素分析

  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係
  • 價值鏈分析
  • 投資可行性分析
  • 價格分析

第6章 全球幹細胞治療市場:各類型

  • 簡介
  • 同種異體
  • 自體

第7章 全球幹細胞治療市場:各治療法

  • 簡介
  • 藥物療法
  • 心血管疾病
  • 骨的再生
  • 神經退化性疾病
  • 創傷治療
  • 眼的治療
  • 造血系疾病
  • 代謝障礙
  • 癌症
  • 免疫力缺乏
  • 糖尿病

第8章 全球幹細胞治療市場:各細胞來源

  • 簡介
  • 脂肪組織
  • 骨髓
  • 神經
  • 胚/臍帶血來源
  • IPSCS

第9章 全球幹細胞治療市場:各終端用戶

  • 簡介
  • 生物科技企業
  • 醫院及研究機關
  • 受託研究機構
  • 幹細胞銀行

第10章 全球幹細胞治療市場:各地區

  • 簡介
  • 美國
    • 北美
    • 南美
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 大韓民國
    • 其他的亞太地區
  • 中東、非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 阿曼
    • 科威特
    • 卡達
    • 其他

第11章 企業形勢

  • 簡介
  • 市場佔有率分析
  • 主要的開發與策略
    • 主要的開發

第12章 企業簡介

  • OSIRIS THERAPEUTICS, INC.
    • 企業概要
    • 產品類型概要
    • 財務
    • 主要的開發
    • SWOT分析
  • MEDIPOST CO., LTD.
    • 企業概要
    • 產品類型概要
    • 財務概要
    • 主要的開發
    • SWOT分析
  • ANTEROGEN CO., LTD.
    • 企業概要
    • 產品類型概要
    • 財務概要
    • 主要的開發
    • SWOT分析
  • PHARMICELL CO., LTD.
    • 企業概要
    • 產品類型/業務部門概要
    • 財務概要
    • 主要的開發
    • SWOT分析
  • HOLOSTEM TERAPIE AVANZATE S.R.L.
    • 企業概要
    • 產品類型概要
    • 財務概要
    • 主要的開發
    • SWOT分析
  • JCR PHARMACEUTICALS CO., LTD.
    • 企業概要
    • 產品類型概要
    • 財務概要
    • 主要的開發
    • SWOT分析
  • NUVASIVE, INC
    • 概要
    • 產品類型概要
    • 財務
    • 主要的開發
    • SWOT分析
  • RTI SURGICAL, INC.
    • 概要
    • 產品類型概要
    • 財務
    • 主要的開發
    • SWOT分析
  • ALLOSOURCE
    • 概要
    • 產品類型概要
    • 財務
    • 主要的開發
    • SWOT分析
  • THERMO FISHER SCIENTIFIC
    • 概要
    • 產品類型概要
    • 財務
    • 主要的開發
    • SWOT分析
  • 其他

第13章 附錄

目錄
Product Code: MRFR/HC/4961-CR

Global Stem Cells Therapy Market Forecast till 2027

Market Overview

The stem cell therapy market is expected to attain a significant CAGR of 10.74% during the review period of 2020 to 2027. Stem cell therapy is used to cure any disease. The global market growth is attributed to the rising prevalence of chronic diseases, expanding healthcare industry, and the growing expenditure on medical research. Additionally, the increasing number of clinical studies for stem cell therapy are fuelling the global market growth during the review period.

The global stem cells therapy market is expected to register a healthy market expansion during the forecast period owing to the largest market value of USD 5,735.12 million in 2020. Moreover, an increment in the number of clinical investigations for stem cell therapy is, driving the market development. In any case, the moral worries identified with early-stage stem cell-based treatments and the related significant expenses might hamper the stem cell therapy market development in the future.

Market Segmentation

The stem cell therapy market has been classified in terms of cell source, type, application, and end-user.

Based on cell source the market is classified into adipose tissue, bone marrow, embryo/cord blood-derived, neural, IPSCs, and PSCs.

Based on type, the stem cell therapy market is divided into allogenic and autologous.

By application, the market is classified into diabetes, musculoskeletal disorders, cancer, cardiovascular disorders, gastrointestinal diseases, and others.

In terms of end-user, the global market is categorized into hospitals & clinics, academic research centers, and others.

Regional Analysis

Geographically the stem cell therapy market is spread across the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The expanded public-private financing and exploration awards for delivering protected and successful stem cell therapy items and the presence of central members in the locale are the main considerations driving America's stem cell therapy market.

Europe holds the second biggest portion of the overall industry because of an increment in the eagerness of patients to go through stem cell therapy and a developing number of instances of persistent and neurological problems.

Asia-Pacific is the quickest developing territorial market for stem cell treatments as it is growing quickly and has seen the rise of numerous players. In addition, the rising pervasiveness of disease, and developing reception of stem cell therapy medicines in the area, are probably going to drive the market's development.

The stem cell therapy market in the Middle East& Africa is relied upon to observe confined development because of an absence of public mindfulness and restricted reasonableness among the populace. Be that as it may, some regenerative medication applications are occurring in the Gulf nations.

Major Players

The key companies listed in the stem cell therapy market report Seraxis, Inc. (Germany), ViaCyte, Inc. (the US), Betalin Therapeutics Ltd (Israel), 4.NextCell Pharma AB (US), Kadimastem (Israel), Vertex Pharmaceuticals (US), Fresenius Medical Care AG & Co. KGaA (Germany), Sernava Corp (Canada), Novo Nordisk A/S (Denmark), and Generex Biotechnology (Canada).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

CHAPTER 1. REPORT PROLOGUE

CHAPTER 2. MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
    • 2.2.1 RESEARCH OBJECTIVE
    • 2.2.2 ASSUMPTIONS
    • 2.2.3 LIMITATIONS

CHAPTER 3. RESEARCH METHODOLOGY

  • 3.1 INTRODUCTION
  • 3.2 PRIMARY RESEARCH
  • 3.3 SECONDARY RESEARCH
  • 3.4 MARKET SIZE ESTIMATION

CHAPTER 4. MARKET DYNAMICS

  • 4.1 DRIVERS
  • 4.2 RESTRAINTS
  • 4.3 OPPORTUNITIES
  • 4.4 CHALLENGES
  • 4.5 MACROECONOMIC INDICATORS
  • 4.6 TECHNOLOGY TRENDS & ASSESSMENT

CHAPTER 5. MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 VALUE CHAIN ANALYSIS
  • 5.3 INVESTMENT FEASIBILITY ANALYSIS
  • 5.4 PRICING ANALYSIS

CHAPTER 6. GLOBAL STEM CELL THERAPY MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 ALLOGENEIC
  • 6.3 AUTOLOGOUS

CHAPTER 7. GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 MEDICINE
  • 7.3 CARDIOVASCULAR DISEASES
  • 7.4 BONE REGENERATION
  • 7.5 NEURODEGENERATIVE DISORDERS
  • 7.6 WOUND HEALING
  • 7.7 TREATMENT OF EYES
  • 7.8 HEMATOPOIETIC DISORDERS
  • 7.9 METABOLIC DISORDERS
  • 7.10 CANCER
  • 7.11 IMMUNODEFICIENCY
  • 7.12 DIABETES

CHAPTER 8. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE

  • 8.1 INTRODUCTION
  • 8.2 ADIPOSE TISSUE
  • 8.3 BONE MARROW
  • 8.3 NEURAL
  • 8.4 EMBRYO/CORD BLOOD-DERIVED
  • 8.5 IPSCS

CHAPTER 9. GLOBAL STEM CELL THERAPY MARKET, BY END -USER

  • 9.1 INTRODUCTION
  • 9.2 BIOTECHNOLOGY COMPANIES
  • 9.3 HOSPITALS & RESEARCH INSTITUTES
  • 9.4 CONTRACT RESEARCH ORGANIZATIONS
  • 9.5 STEM CELL BANKS

CHAPTER 10. GLOBAL STEM CELL THERAPY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 AMERICA
    • 10.2.1 NORTH AMERICA
      • 10.2.1.1 US
      • 10.2.1.2 CANADA
    • 10.2.2 SOUTH AMERICA
  • 10.3 EUROPE
    • 10.3.1 WESTERN EUROPE
      • 10.3.1.1 GERMANY
      • 10.3.1.2 FRANCE
      • 10.3.1.3 ITALY
      • 10.3.1.4 SPAIN
      • 10.3.1.5 UK
      • 10.3.1.6 REST OF WESTERN EUROPE
    • 10.3.2 EASTERN EUROPE
  • 10.4 ASIA-PACIFIC
    • 10.4.1 JAPAN
    • 10.4.2 CHINA
    • 10.4.3 INDIA
    • 10.4.4 AUSTRALIA
    • 10.4.5 REPUBLIC OF KOREA
    • 10.4.6 REST OF ASIA-PACIFIC
  • 10.5 MIDDLE EAST & AFRICA
    • 10.5.1 UNITED ARAB EMIRATES
    • 10.5.2 SAUDI ARABIA
    • 10.5.3 OMAN
    • 10.5.4 KUWAIT
    • 10.5.5 QATAR
    • 10.5.6 REST OF THE MIDDLE EAST & AFRICA

CHAPTER 11. COMPANY LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS
  • 11.3 KEY DEVELOPMENT & STRATEGIES
    • 11.3.1 KEY DEVELOPMENTS

CHAPTER 12 COMPANY PROFILES

  • 12.1 OSIRIS THERAPEUTICS, INC.
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 PRODUCT TYPE OVERVIEW
    • 12.1.3 FINANCIALS
    • 12.2.4 KEY DEVELOPMENTS
    • 12.1.5 SWOT ANALYSIS
  • 12.2 MEDIPOST CO., LTD.
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 PRODUCT TYPE OVERVIEW
    • 12.2.3 FINANCIAL OVERVIEW
    • 12.2.4 KEY DEVELOPMENTS
    • 12.2.5 SWOT ANALYSIS
  • 12.3 ANTEROGEN CO., LTD.
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 PRODUCT TYPE OVERVIEW
    • 12.3.3 FINANCIAL OVERVIEW
    • 12.3.4 KEY DEVELOPMENT
    • 12.3.5 SWOT ANALYSIS
  • 12.4 PHARMICELL CO., LTD.
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 PRODUCT TYPE/BUSINESS SEGMENT OVERVIEW
    • 12.4.3 FINANCIAL OVERVIEW
    • 12.4.4 KEY DEVELOPMENT
    • 12.4.5 SWOT ANALYSIS
  • 12.5 HOLOSTEM TERAPIE AVANZATE S.R.L.
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 PRODUCT TYPE OVERVIEW
    • 12.5.3 FINANCIAL OVERVIEW
    • 12.5.4 KEY DEVELOPMENTS
    • 12.5.5 SWOT ANALYSIS
  • 12.6 JCR PHARMACEUTICALS CO., LTD.
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 PRODUCT TYPE OVERVIEW
    • 12.6.3 FINANCIAL OVERVIEW
    • 12.6.4 KEY DEVELOPMENTS
    • 12.6.5 SWOT ANALYSIS
  • 12.7 NUVASIVE, INC
    • 12.7.1 OVERVIEW
    • 12.7.2 PRODUCT TYPE OVERVIEW
    • 12.7.3 FINANCIALS
    • 12.7.4 KEY DEVELOPMENTS
    • 12.7.5 SWOT ANALYSIS
  • 12.8 RTI SURGICAL, INC.
    • 12.8.1 OVERVIEW
    • 12.8.2 PRODUCT TYPE OVERVIEW
    • 12.8.3 FINANCIALS
    • 12.8.4 KEY DEVELOPMENTS
    • 12.8.5 SWOT ANALYSIS
  • 12.9 ALLOSOURCE
    • 12.9.1 OVERVIEW
    • 12.9.2 PRODUCT TYPE OVERVIEW
    • 12.9.3 FINANCIALS
    • 12.9.4 KEY DEVELOPMENTS
    • 12.9.5 SWOT ANALYSIS
  • 12.10 THERMO FISHER SCIENTIFIC
    • 12.10.1 OVERVIEW
    • 12.10.2 PRODUCT TYPE OVERVIEW
    • 12.10.3 FINANCIALS
    • 12.10.4 KEY DEVELOPMENTS
    • 12.10.5 SWOT ANALYSIS
  • 12.11 OTHERS

CHAPTER 14 APPENDIX

LIST OF TABLES

  • TABLE 1 STEM CELL THERAPY MARKET INDUSTRY SYNOPSIS, 2020-2027
  • TABLE 2 GLOBAL STEM CELL THERAPY MARKET ESTIMATES & FORECAST, 2020-2027, (USD MILLION)
  • TABLE 3 GLOBAL STEM CELL THERAPY MARKET, BY REGION, 2020-2027, (USD MILLION)
  • TABLE 4 GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 5 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 7 GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 8 GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION
  • TABLE 9 NORTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 10 NORTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 12 NORTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 13 NORTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 14 US: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 15 US: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 17 US: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 18 US: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 19 CANADA: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 20 CANADA: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 22 CANADA: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 23 CANADA: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 24 SOUTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 25 SOUTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 27 SOUTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 28 SOUTH AMERICA: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 29 EUROPE: GLOBAL STEM CELL THERAPY MARKET, TYPE, 2020-2027, (USD MILLION)
  • TABLE 30 EUROPE: GLOBAL STEM CELL THERAPY MARKET, THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 32 EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 33 EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 34 WESTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 35 WESTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 37 WESTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 38 WESTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION
  • TABLE 39 EASTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 40 EASTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 42 EASTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 43 EASTERN EUROPE: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 44 ASIA-PACIFIC: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 45 ASIA-PACIFIC: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 47 ASIA-PACIFIC: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 48 ASIA-PACIFIC: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)
  • TABLE 49 MIDDLE EAST & AFRICA: GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2020-2027, (USD MILLION)
  • TABLE 50 MIDDLE EAST & AFRICA: GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027, (USD MILLION)
  • TABLE 52 MIDDLE EAST & AFRICA: GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027, (USD MILLION)
  • TABLE 53 MIDDLE EAST & AFRICA: GLOBAL STEM CELL THERAPY MARKET, BY END-USER, 2020-2027, (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 RESEARCH PROCESS
  • FIGURE 2 SEGMENTATION FOR THE GLOBAL STEM CELL THERAPY MARKET
  • FIGURE 3 MARKET DYNAMICS FOR GLOBAL STEM CELL THERAPY MARKET
  • FIGURE 4 GLOBAL STEM CELL THERAPY MARKET SHARE, BY TYPE 2020
  • FIGURE 4 GLOBAL STEM CELL THERAPY MARKET SHARE, BY PRODUCT TYPE 2020
  • FIGURE 5 GLOBAL STEM CELL THERAPY MARKET SHARE, BY CELL SOURCE 2020
  • FIGURE 6 GLOBAL STEM CELL THERAPY MARKET SHARE, BY END-USER, 2020
  • FIGURE 7 GLOBAL STEM CELL THERAPY MARKET SHARE, BY REGION, 2020
  • FIGURE 8 NORTH AMERICA STEM CELL THERAPY MARKET SHARE, BY COUNTRY, 2020
  • FIGURE 9 EUROPE STEM CELL THERAPY MARKET SHARE, BY COUNTRY, 2020
  • FIGURE 10 ASIA-PACIFIC STEM CELL THERAPY MARKET SHARE, BY COUNTRY, 2020
  • FIGURE 11 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SHARE, BY COUNTRY, 2020
  • FIGURE 12 GLOBAL STEM CELL THERAPY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
  • FIGURE 13 OSIRIS THERAPEUTICS, INC.: KEY FINANCIALS
  • FIGURE 14 OSIRIS THERAPEUTICS, INC.: SEGMENTAL REVENUE
  • FIGURE 15 OSIRIS THERAPEUTICS, INC.: GEOGRAPHICAL REVENUE
  • FIGURE 16 MEDIPOST CO., LTD.: KEY FINANCIALS
  • FIGURE 17 MEDIPOST CO., LTD.: SEGMENTAL REVENUE
  • FIGURE 18 MEDIPOST CO., LTD.: GEOGRAPHICAL REVENUE
  • FIGURE 19 ANTEROGEN CO., LTD.: KEY FINANCIALS
  • FIGURE 20 ANTEROGEN CO., LTD.: SEGMENTAL REVENUE
  • FIGURE 21 ANTEROGEN CO., LTD.: GEOGRAPHICAL REVENUE
  • FIGURE 22 PHARMICELL CO., LTD.: KEY FINANCIALS
  • FIGURE 23 PHARMICELL CO., LTD.: SEGMENTAL REVENUE
  • FIGURE 24 PHARMICELL CO., LTD.: GEOGRAPHICAL REVENUE
  • FIGURE 25 JCR PHARMACEUTICALS CO., LTD.: KEY FINANCIALS
  • FIGURE 26 JCR PHARMACEUTICALS CO., LTD.: SEGMENTAL REVENUE
  • FIGURE 27 JCR PHARMACEUTICALS CO., LTD.: GEOGRAPHICAL REVENUE
  • FIGURE 28 HOLOSTEM TERAPIE AVANZATE S.R.L.: KEY FINANCIALS
  • FIGURE 29 HOLOSTEM TERAPIE AVANZATE S.R.L. : SEGMENTAL REVENUE
  • FIGURE 30 HOLOSTEM TERAPIE AVANZATE S.R.L.: GEOGRAPHICAL REVENUE
  • FIGURE 31 NUVASIVE, INC: KEY FINANCIALS
  • FIGURE 32 NUVASIVE, INC: SEGMENTAL REVENUE
  • FIGURE 33 NUVASIVE, INC: GEOGRAPHICAL REVENUE
  • FIGURE 34 RTI SURGICAL, INC.: KEY FINANCIALS
  • FIGURE 35 RTI SURGICAL, INC.: SEGMENTAL REVENUE
  • FIGURE 36 RTI SURGICAL, INC.: GEOGRAPHICAL REVENUE
  • FIGURE 37 ALLOSOURCE: KEY FINANCIALS
  • FIGURE 38 ALLOSOURCE: SEGMENTAL REVENUE
  • FIGURE 39 ALLOSOURCE: GEOGRAPHICAL REVENUE
  • FIGURE 40 THERMO FISHER SCIENTIFIC: KEY FINANCIALS
  • FIGURE 41 THERMO FISHER SCIENTIFIC: SEGMENTAL REVENUE
  • FIGURE 42 THERMO FISHER SCIENTIFIC: GEOGRAPHICAL REVENUE